Phase II DIMOND Study [Dimebon] Results Are Very Encouraging
HDSA Breaking News by Marsha Miller
http://www.hdsa.org/research/news/815.html

Not only is it safe and well-tolerated by HD patients, but after only three
months, they got statistically significant results on a cognitive test, the
Mini Mental States Exam. In addition, the Dimebon group was almost half as
likely to fall as the placebo group.

"To my knowledge, no other drug has resulted in statistically significant
benefit in cognition in Huntington's disease patients in a randomized,
well-controlled trial," said Karl Kieburtz, M.D., M.P.H., professor of
neurology at the University of Rochester, director of the HSG Clinical
Trials Coordination Center, and principal investigator in this trial.
"Cognitive impairment is the most important therapeutic unmet need in
Huntington's disease. I am pleased by this result and Dimebon's favorable
safety profile, and believe that further development of this compound is
warranted."

Thank you Marsha for getting this exciting news on-line so
quickly......Medivation just hosted a conference call TODAY on the results
of this study!!!!!

Medivation's release:
http://investors.medivation.net//ReleaseDetail.cfm?ReleaseID=320002